A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
← catalyst calendarNCT07776509 · readout in 719 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
500estimated
Sites
88
Countries
Argentina, Brazil, Canada +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-20
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-21 | estimated | When the study began enrolling |
| Primary completion | 2028-08-09 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-09 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity or Overweight
- Weight-Related Comorbidity
- With/Without Diabetes Mellitus, Type 2
Interventions
- Drug: AZD6234
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent change in body weight from baseline at 68 weeks of treatment
measured 68 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed